STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE AND EPLERENONE IN ITS SYNTHETIC MIXTURE

Metabolic disorders are increasingly recognized as systemic conditions with significant effects on both cardiac and renal health. Type 2 diabetes mellitus substantially contributes to the development and progression of cardiovascular disease and chronic kidney impairment through complex metabolic and hormonal disturbances.[1] Pharmacological agents that influence renal sodium handling have shown potential to modify disease outcomes beyond glycemic control. Dapagliflozin, an inhibitor of sodium–glucose cotransporter-2, facilitates glucose and sodium excretion via the kidneys, leading to beneficial metabolic and hemodynamic effects.[2] Eplerenone, a selective mineralocorticoid receptor antagonist, counteracts aldosterone-driven fluid retention and tissue fibrosis with improved tolerability.[2,3] The concurrent use of dapagliflozin and eplerenone targets distinct yet interrelated pathways within the cardio-renal system and may provide enhanced protective effects in patients with kidney and heart dysfunction.[2,3] Ongoing monitoring of renal function and electrolyte balance remains essential during combined therapy.